Voyager Therapeutics (DB:VT6) - Stock Price, News & Analysis

VT6 Stock Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases.

VT6 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (3.1x) is below the German market (17.1x)

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 40.3% per year for the next 3 years

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Voyager Therapeutics, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

PharmaSGP Holding

XTRA:PSG

€261.6m

Clinuvel Pharmaceuticals

ASX:CUV

AU$751.1m

Dermapharm Holding

XTRA:DMP

€1.7b

Price History & Performance

Summary of all time highs, changes and price drops for Voyager Therapeutics
Historical stock prices
Current Share Price	US$7.23
52 Week High	US$13.20
52 Week Low	US$5.60
Beta	0.95
1 Month Change	-11.35%
3 Month Change	3.21%
1 Year Change	7.04%
3 Year Change	74.26%
5 Year Change	-62.99%
Change since IPO	-60.67%

Recent updates

Shareholder Returns

	VT6	DE Biotechs	DE Market
7D	-3.9%	-1.2%	1.7%
1Y	7.0%	-23.0%	2.3%

Return vs Industry: VT6 exceeded the German Biotechs industry which returned -22.4% over the past year.

Return vs Market: VT6 exceeded the German Market which returned 2.2% over the past year.

Price Volatility

Is VT6's price volatile compared to industry and market?
VT6 volatility
VT6 Average Weekly Movement	11.4%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: VT6's share price has been volatile over the past 3 months.

Volatility Over Time: VT6's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2013	162	Al Sandrock	www.voyagertherapeutics.com

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.

Voyager Therapeutics, Inc. Fundamentals Summary

How do Voyager Therapeutics's earnings and revenue compare to its market cap?
VT6 fundamental statistics
Market cap	€388.15m
Earnings (TTM)	€123.65m
Revenue (TTM)	€233.61m

3.1x

P/E Ratio

1.6x

P/S Ratio

Is VT6 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VT6 income statement (TTM)
Revenue	US$250.01m
Cost of Revenue	US$92.17m
Gross Profit	US$157.84m
Other Expenses	US$25.51m
Earnings	US$132.33m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	2.44
Gross Margin	63.13%
Net Profit Margin	52.93%
Debt/Equity Ratio	0%

How did VT6 perform over the long term?

See historical performance and comparison

VT6 Stock Overview

Rewards

Risk Analysis

Voyager Therapeutics, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:PSG

€261.6m

ASX:CUV

AU$751.1m

XTRA:DMP

€1.7b

Price History & Performance

Recent News & Updates

President recently sold €111k worth of stock

Investor sentiment improves as stock rises 17%

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022)

Investor sentiment improves as stock rises 27%

Recent updates

President recently sold €111k worth of stock

Investor sentiment improves as stock rises 17%

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022)

Investor sentiment improves as stock rises 27%

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

President recently sold €90k worth of stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New major risk - Shareholder dilution

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Investor sentiment improves as stock rises 26%

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.46 profit in 3Q 2022)

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold €91k worth of stock

Second quarter 2023 earnings released: US$0.51 loss per share (vs US$0.50 loss in 2Q 2022)

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Investor sentiment deteriorates as stock falls 16%

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 19%

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022)

President recently sold €54k worth of stock

Chief Operating Officer recently sold €120k worth of stock

Full year 2022 earnings released: US$1.21 loss per share (vs US$1.89 loss in FY 2021)

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021)

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022

Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021)

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors

Voyager Therapeutics, Inc. Announces Executive Changes

Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction

Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.58 loss in 1Q 2021)

Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022

Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. Announces Executive Appointments

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$2.30 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020)

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.66 loss in 1Q 2020)

Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS US$0.99 (vs US$1.21 loss in FY 2019)

Revenue misses expectations